Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma

Date: October 1, 2023

BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.

Pomalidomide Combo Yields PFS/OS Benefits in R/R Multiple Myeloma

Date: October 1, 2023

Pomalidomide plus bortezomib and dexamethasone confers a larger progression-free survival benefit than bortezombib plus dexamethasone among patients with relapsed/refractory multiple myeloma in the phase 3 OPTIMISMM trial.

ctDNA Pushes Its Prognostic Role in Large Cell Lymphomas

Date: October 1, 2023

For large cell lymphomas, physicians typically use CT and positron emission tomography-computed tomography scans to look for signs of minimum residual disease when treatment is completed.

FDA Awards Orphan Drug Designation to Alisertib in ES-SCLC

Date: October 1, 2023

The FDA has granted an orphan drug designation to alisertib (MLN8237) for the treatment of patients with extensive-stage small cell lung cancer.

Venetoclax-Based Triplet Demonstrates Early Efficacy in t(11;14)-Positive RRMM

Date: September 30, 2023

Positive response and preliminary evidence of longer progression-free survival was observed with a venetoclax-based triplet therapy vs a doublet, in a phase. 2 study.

Odronextamab Receives FDA Priority Review in R/R DLBCL/Follicular Lymphoma

Date: September 30, 2023

The biologic license application for odronextamab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma is based on data from the phase 1 ELM- 1 and phase 2 ELM-2 studies.

Cilta-Cel Achieved PFS Prolongation in Patients With Myeloma and Poor Prognosis

Date: September 30, 2023

The observed benefits of ciltacabtagene autoleucel in patients with multiple myeloma and poor prognostic features are consistent with the overall the population of CARTITUDE-4.

Novel Drugs May Introduce ‘New Era’ of Metastatic Prostate Cancer Treatment

Date: September 30, 2023

Neeraj Agarwal, MD, states that he is optimistic about the development of new treatment options including immunotherapies, CAR T-cell therapies, and antibody-drug conjugates for metastatic prostate cancer.

Dr Liu on Epigenetic Regulation of CD38/CD48 in Multiple Myeloma

Date: September 30, 2023

Jiye Liu, PhD, discusses epigenetic regulation of CD38/CD48 in multiple myeloma.

Anti-BCMA CAR T-Cell Therapy Displays Safety in R/R AL Amyloidosis

Date: September 30, 2023

NXC-201 has demonstrated safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.

Dr Rasche on BCMA and GPRC5D Loss After Bispecific Antibody Therapy in Multiple Myeloma

Date: September 30, 2023

Leo Rasche, MD, discusses BCMA and GPRC5D loss after bispecific antibody therapy in multiple myeloma.

Cilta-Cel Shows PFS Benefit in Patients With Multiple Myeloma and Poor Prognostic Features

Date: September 30, 2023

In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel was shown to be effective when used in patients with multiple myeloma exhibiting poor prognostic features.

Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma

Date: September 30, 2023

The addition of venetoclax to carfilzomib and dexamethasone increased response rates compared with carfilzomib plus dexamethasone alone in patients with t(11:14)-positive relapsed/refractory multiple myeloma.

NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL Amyloidosis

Date: September 30, 2023

The novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.

Investigation of Novel BTK Degrader Continues in CLL

Date: September 30, 2023

In an interview with Targeted Oncology, Justin Taylor, MD, discussed early research on NX-2127, a BTK degrader being evaluated for the treatment of chronic lymphocytic leukemia.

Roundtable Roundup: Physicians Choose Frontline Therapy for Multiple Myeloma

Date: September 30, 2023

At separate live virtual events, Brea C. Lipe, MD, and Amandeep Godara, MD, MBBS, discussed options for the same elderly patient with multiple myeloma who is not able to receive a transplant.

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

Date: September 30, 2023

Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.

CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance in Multiple Myeloma

Date: September 29, 2023

The EZH2 inhibitor tazemetostat may mimic the role of the KDM6A gene in upregulating CD38 and CD48 expression, suggesting that this agent could restore responses to daratumamab in patients with multiple myeloma, according to a presentation at the 20th International Myeloma Society Annual Meeting.

IberVd Generates Long-Lasting Responses in Newly Diagnosed, Transplant-Ineligible MM

Date: September 29, 2023

IberVd showed high efficacy with deep, ongoing responses among older patients with transplant-ineligible, newly diagnosed multiple myeloma.

Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLC

Date: September 29, 2023

Mitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.

Dr Ricciuti on PD-L1 Expression and Long-Term Survival Outcomes With PD-L1 Inhibitors in Advanced NSCLC

Date: September 29, 2023

Biagio Ricciuti, MD, discusses the association between PD-L1 expression levels and long-term survival with anti–PD-L1 monotherapy in patients with advanced non–small cell lung cancer.

IberVd Elicits Durable Responses in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

Date: September 29, 2023

The combination of iberdomide plus bortezomib and dexamethasone produced deep responses with a manageable toxicity profile in patients with transplant-ineligible, newly diagnosed multiple myeloma, according to data from the phase 1/2 CC-220-MM-001 trial presented at the 2023 International Myeloma Society Annual Meeting.

Dr Reed on Genetic Differences Between Ewing Sarcoma and Osteosarcoma

Date: September 29, 2023

Damon R. Reed, MD, discusses the genetic differences that distinguish Ewing sarcoma from osteosarcoma, as well as unmet needs in patients with these diseases.

NK Cell Response Mediated by CD38/48 Regulation With Daratumumab in Multiple Myeloma

Date: September 29, 2023

Researchers identified KDM6A’s role in CD38 regulation and found that an EZH2 inhibitor could potentially reduce resistance to an anti-CD38 antibody in multiple myeloma cells.

Dr Velázquez Mañana on Survivorship Care Needs in Older Patients With Lung Cancer

Date: September 29, 2023

Ana Velázquez Mañana, MD, discusses findings from a study determining survivorship care needs in low-income, older patients with lung cancer.

Teclistamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-Directed Therapy

Date: September 29, 2023

Treatment with teclistamab led to responses in patients with relapsed/refractory multiple myeloma, including those previously exposed to anti-BCMA therapies.

Forimtamig Delivers Responses in Relapsed/Refractory Multiple Myeloma

Date: September 29, 2023

Forimtamig monotherapy generated high overall response rates and durable responses in all subgroups of patients with relapsed/refractory multiple myeloma enrolled in a phase 1a dose-escalation trial.

Teclistamab Elicits Efficacy in RRMM, Despite Prior Anti-BCMA Therapy

Date: September 29, 2023

Although response rates were lower among patients given previous anti-BCMA therapy, teclistamab shows promise for all patients with relapsed/refractory multiple myeloma.

Dr Jones on the Application of ctDNA Testing in CRC

Date: September 29, 2023

Jeremy C. Jones, MD, discusses the applications of circulating tumor DNA testing in colorectal cancer.

Forimtamig Shows Deep, Durable Responses in Relapsed/Refractory Multiple Myeloma

Date: September 29, 2023

At a median duration of response of 12.2 months, the objective response rates with forimtamig across all dose levels was 66.7% with a very good partial response rate of 54.2%, according to data from a phase 1a dose-escalation trial.

Dr Chaudhary on the Utilization of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer

Date: September 29, 2023

Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.